Summary
The provided AI claims focus on branding/manufacturing/commercialization and do not align with (or are not supported by) the supplied FDA label excerpts, which only cover serious meningococcal infection warnings, contraindications, and REMS-related counseling/requirements.
Category Scores
Accurate Statements
Eculizumab has the brand name Soliris.
Not supported or referenced in the supplied label excerpts (only warning/REMS content provided).
There can be multiple companies involved with eculizumab across manufacturing, licensing, and distribution.
Not supported or referenced in the supplied label excerpts.
Unsupported Statements
Eculizumab has the brand name Soliris.
The supplied excerpts do not provide a statement linking eculizumab to the Soliris brand name.
Eculizumab (Soliris) is made by AstraZeneca’s subsidiary.
Not addressed in the supplied label excerpts.
AstraZeneca markets Soliris in many countries.
Not addressed in the supplied label excerpts.
Eculizumab was originally developed by Alexion Pharmaceuticals.
Not addressed in the supplied label excerpts.
Alexion Pharmaceuticals later became part of AstraZeneca.
Not addressed in the supplied label excerpts.
AstraZeneca continued commercialization of eculizumab after the acquisition.
Not addressed in the supplied label excerpts.
AstraZeneca continues distribution of eculizumab under the Soliris brand.
Not addressed in the supplied label excerpts.
The company that markets the branded product is typically the manufacturer people mean for prescriptions.
Not addressed in the supplied label excerpts.
Production of eculizumab can involve contracted or internal facilities.
Not addressed in the supplied label excerpts.
Alternatives to eculizumab are generally limited to the branded originator and any approved substitutes in a given country.
Not addressed in the supplied label excerpts.
Contradictions
Important Omissions
No on-label safety warning content was evaluated or reflected in the provided AI claims, despite the supplied label excerpts emphasizing: (1) increased susceptibility to serious/fatal meningococcal infections, (2) vaccination not eliminating risk, (3) contraindication to initiation in patients with unresolved serious Neisseria meningitidis infection, and (4) REMS requirements (restricted program; prescriber/patient counseling; vaccination timing; prophylaxis when urgent).
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The supplied AI claims are primarily about branding, development, and business relationships and do not include dosing, contraindications, or warning-related instructions that could directly cause harm. However, they omit key on-label safety/contraindication/REMS information from the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Most claims are unsupported because the provided FDA label excerpts do not address branding/manufacturing/commercialization, and none of the key on-label safety/contraindication/REMS content is reflected.
Suggested Improvement
Limit claims to information present in the provided prescribing information excerpt (serious meningococcal infection warning, contraindication for unresolved Neisseria meningitidis infection, vaccination timing, antibacterial prophylaxis for urgent initiation, and ULTOMIRIS/SOLIRIS REMS requirements). Avoid unsourced assertions about corporate relationships, manufacturing, distribution, or alternatives.